A O O
eGFR B_MEASURE B_MEASURE/B_LOCATION
below O O
60 B_MEASURE B_MEASURE/B_LOCATION
indicates O O
chronic B_DISEASE B_DISEASE
kidney I_DISEASE I_DISEASE
disease I_DISEASE I_DISEASE
. O O

Imatinib B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mesylate B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
a O O
kinase O O
inhibitor O O
used O O
to O O
treat O O
adults O O
and O O
pediatric O O
patients O O
with O O
Philadelphia O O
+ O O
chronic O O
myeloid O O
leukemia O O
(Ph+ O O
CML) O O
and O O
other O O
FDA O O
approved O O
indications O O
. O O

It O O
is O O
also O O
indicated O O
for O O
the O O
treatment O O
of O O
patients O O
with O O
locally O O
advanced, O O
unresectable O O
or O O
metastatic O O
gastrointestinal O O
stromal O O
tumor O O
(GIST) O O
who O O
have O O
been O O
previously O O
treated O O
with O O
imatinib B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mesylate I_DRUG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sunitinib B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
malate I_DRUG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
strong O O
enrichment O O
in O O
ruthenium B_CHEMICAL_SUBSTANCE B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaches O O
an O O
apogee O O
at O O
the O O
center O O
of O O
the O O
massive O O
sulphide O O
zone. O O

Mesothelioma B_DISEASE B_DISEASE/B_LOCATION
is O O
caused O O
by O O
exposure O O
to O O
asbestos B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

functionality O O
will O O
alert O O
providers O O
of O O
patients O O
receiving O O
several O O
dispensed O O
opioid O O
prescriptions O O
and O O
identify O O
overlapping O O
dispensed O O
prescriptions O O
of O O
opioids O O
and O O
benzodiazepines B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Acrylic-based O O
adhesives B_CHEMICAL_CLASS B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
used O O
in O O
a O O
wide O O
range O O
of O O
applications O O
for O O
their O O
chemical O O
characteristics O O
and O O
unique O O
aesthetic O O
properties O O
. O O

Colon O O
cleansing O O
efficacy O O
and O O
safety O O
with O O
1L O O
NER1006 O O
versus O O
2L O O
polyethylene O O
glycol O O
+ O O
ascorbate B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
a O O
randomized O O
Phase O O
3 O O
trial O O
. O O

Autoradiography B_LAB_PROCEDURE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
revealed O O
the O O
presence O O
of O O
[ O O
125 O O
I]iododeoxyuridine-labelled O O
lymphoblasts O O
associated O O
with O O
human O O
microvasculature O O
within O O
the O O
xenograft O O
. O O

Chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
works O O
by O O
disrupting O O
the O O
way O O
that O O
cancer O O
cells O O
grow O O
and O O
divide O O
. O O

DNA O O
samples O O
for O O
prenatal O O
testing O O
can O O
be O O
obtained O O
by O O
amniocentesis B_DIAGNOSTIC_PROCEDURE B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
chorionic O O
villus O O
sampling, O O
or O O
even O O
by O O
the O O
analysis O O
of O O
rare O O
fetal O O
cells O O
circulating O O
in O O
the O O
mother's O O
bloodstream O O
. O O

comparison O O
of O O
serum O O
concentrations B_LAB_TEST_COMPONENT B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
symmetric O O
dimethylarginine O O
and O O
creatinine O O
as O O
kidney O O
function O O
biomarkers O O
in O O
cats O O
with O O
chronic O O
kidney O O
disease O O
. O O

In O O
the O O
LASOR B_STUDY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
increasing O O
daily O O
imatinib O O
dose O O
from O O
400 O O
to O O
600mg O O
induced O O
MMR O O
at O O
12 O O
and O O
24 O O
months O O
in O O
25% O O
and O O
36% O O
of O O
the O O
patients, O O
respectively, O O
who O O
had O O
suboptimal O O
cytogenetic O O
responses O O
. O O

Currently, O O
there O O
are O O
no O O
approved B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapies O O
available O O
for O O
CML B_DISEASE B_DISEASE/B_PERSON
patients O O
who O O
fail O O
dasatinib B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
nilotinib B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
second O O
line O O
. O O

patients O O
with O O
pre-existing O O
hypertension O O
may O O
be O O
more O O
susceptible O O
to O O
the O O
hypertensive B_DISEASE_ADJECTIVE B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
. O O

At O O
these O O
levels, O O
alcohol O O
can O O
also O O
cause O O
blackouts O O
which O O
are O O
periods O O
of O O
amnesia B_MENTAL_OR_BEHAVIORAL_DYSFUNCTION B_DISEASE_ADJECTIVE[DISEASE]
where O O
a O O
person O O
does O O
not O O
remember O O
what O O
happened O O
while O O
he O O
or O O
she O O
was O O
intoxicated O O
. O O

Tatyana O O
was O O
born O O
with O O
spina B_CONGENITAL_ABNORMALITY B_DISEASE/B_BACTERIUM[BIO]
bifida I_CONGENITAL_ABNORMALITY I_DISEASE/I_BACTERIUM[BIO]
and O O
spent O O
the O O
first O O
six O O
years O O
of O O
her O O
life O O
in O O
a O O
Russian O O
orphanage O O
with O O
no O O
access O O
to O O
a O O
wheelchair O O
. O O

There O O
is O O
a O O
tremendous O O
unmet O O
medical O O
need O O
for O O
children O O
suffering O O
with O O
esophageal O O
atresia B_CONGENITAL_ABNORMALITY B_DISEASE
in O O
the O O
United O O
States O O
and O O
across O O
the O O
world O O
. O O

His O O
laboratory O O
studies O O
mechanisms O O
of O O
neurodegeneration B_CELL_OR_MOLECULAR_DYSFUNCTION B_DISEASE/B_GENE
in O O
Parkinson's O O
disease, O O
with O O
a O O
focus O O
on O O
gene-environment O O
interactions O O
. O O

Overexpression O O
of O O
EGFR B_GENE B_GENE
occurs O O
across O O
a O O
wide O O
range O O
of O O
different O O
cancers O O
. O O

Niacin O O
has O O
potential O O
to O O
enhance O O
adiposity, O O
insulin O O
sensitivity, O O
glucose O O
tolerance, O O
and O O
lipid O O
profile, O O
while O O
modulating O O
adiponectin B_GENE B_GENE
level, O O
thereby O O
complementing O O
obesity O O
management O O
effectively O O
. O O

Ensemble O O
candidate O O
results O O
for O O
input: O O
PAI-1 O O
inhibits O O
the O O
serine O O
proteases O O
tPA O O
and O O
urokinase B_GENE B_GENE/B_LOCATION
and O O
hence O O
inhibit O O
the O O
physiological O O
process O O
that O O
degrades O O
blood O O
clots O O
. O O

activity O O
of O O
plasmin O O
is O O
improved O O
when O O
urokinase B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
given O O
in O O
the O O
form O O
of O O
an O O
intravenous O O
drip O O
and O O
falls O O
back O O
to O O
normal O O
level O O
several O O
hours O O
later. O O

In O O
2008, O O
Microbix O O
completed O O
the O O
acquisition O O
of O O
all O O
urokinase B_STUDY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assets I_STUDY I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
ImaRx O O
Therapeutics, O O
Inc., O O
making O O
Microbix O O
the O O
only O O
worldwide O O
source O O
of O O
low-molecular-weight O O
urokinase B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Additionally, O O
the O O
report O O
provides O O
an O O
overview O O
of O O
key O O
players O O
involved O O
in O O
surface O O
protein O O
gp120 B_VIRAL_PROTEIN B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
targeted O O
therapeutics O O
development O O
and O O
features O O
dormant O O
and O O
discontinued O O
projects O O
. O O

Studies O O
of O O
mice O O
injected O O
with O O
gp120 B_VIRAL_PROTEIN B_GENE
confirmed O O
an O O
insufficient O O
IgG O O
response O O
to O O
the O O
CD4 O O
binding O O
site O O
. O O

Phosphorylation O O
of O O
PPARgamma B_RECEPTOR B_GENE
via O O
active O O
ERK1/2 O O
leads O O
to O O
its O O
physical O O
association O O
with O O
p65 O O
and O O
inhibition O O
of O O
NF-kappabeta O O
. O O

The O O
structural O O
and O O
regulatory O O
properties O O
of O O
proteoglycans B_PROTEIN_FAMILY B_GENE
have O O
potential O O
applications O O
in O O
a O O
wide O O
variety O O
of O O
disease O O
states O O
. O O

targeting O O
both O O
suPAR O O
and O O
dynamin B_MOUSE_PROTEIN_FAMILY B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
beneficial O O
across O O
numerous O O
types O O
of O O
renal O O
diseases O O
. O O

It O O
has O O
long O O
been O O
hypothesized O O
that O O
malfunctioning O O
inhibitory O O
control O O
over O O
the O O
amygdala B_BODY_PART_OR_ORGAN_COMPONENT B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
could O O
result O O
in O O
depressive O O
symptoms O O
. O O

Typically, O O
cements O O
form O O
a O O
strong O O
bond O O
with O O
enamel B_CHEMICAL_SUBSTANCE B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
dentin, O O
ensuring O O
the O O
stability O O
of O O
metal O O
and O O
ceramic O O
restorations O O
in O O
the O O
patient's O O
mouth O O
. O O

Cathepsin O O
L O O
promote O O
tumor O O
cell O O
invasion O O
and O O
metastasis O O
by O O
catalyzing O O
degradation O O
of O O
the O O
interstitial B_CELL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
matrix O O
and O O
basement O O
membranes O O
. O O

In O O
Checkmate O O
205 O O
and O O
039, O O
pneumonitis, O O
including O O
interstitial B_DISEASE_ADJECTIVE B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lung O O
disease, O O
occurred O O
in O O
6.0% O O
(16/266) O O
of O O
patients O O
receiving O O
OPDIVO O O
. O O

Cell O O
therapy O O
approaches O O
include O O
attempts O O
to O O
reinitiate O O
cardiomyocyte B_CELL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
proliferation O O
in O O
the O O
adult, O O
conversion O O
of O O
fibroblasts B_CELL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
contractile O O
myocytes B_CELL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
conversion O O
of O O
bone O O
marrow O O
stem O O
cells O O
into O O
cardiomyocytes B_CELL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
transplantation O O
of O O
myocytes O O
or O O
other O O
cells O O
into O O
injured O O
myocardium O O
. O O

Using O O
this O O
dose, O O
SY5Y B_CELL_LINE B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O O
were O O
incubated O O
with O O
BPA O O
for O O
various O O
durations O O
(from O O
0 O O
to O O
24h) O O
. O O

The O O
system O O
bombards O O
plant O O
tissue O O
with O O
the O O
genes O O
of O O
interest, O O
prompting O O
chloroplasts B_BIO B_BIO/B_PERSON
to O O
take O O
up O O
genes O O
and O O
then O O
express O O
that O O
protein O O
. O O

He O O
received O O
a O O
$70,000 O O
award O O
for O O
his O O
project O O
designing O O
a O O
process O O
to O O
induce O O
photosynthesis O O
in O O
human O O
stem O O
cells, O O
allowing O O
them O O
to O O
produce O O
their O O
own O O
oxygen, O O
by O O
inserting O O
chloroplasts B_CELL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
spinach O O
. O O

The O O
island O O
abounds O O
with O O
hiking O O
trails, O O
jungle O O
valleys, O O
coconut B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plantations O O
and O O
hot O O
springs O O
year O O
round O O
. O O

Burkholderia B_BACTERIUM B_BACTERIUM[BIO]/B_DISEASE
cepacia I_BACTERIUM I_BACTERIUM[BIO]/I_DISEASE
and O O
group O O
of O O
related O O
strains O O
rarely O O
cause O O
infections O O
in O O
healthy O O
people, O O
but O O
pose O O
serious O O
risk O O
to O O
individuals O O
with O O
cystic O O
fibrosis, O O
weakened O O
immune O O
systems, O O
and O O
chronic O O
lung O O
disease O O
. O O

However, O O
the O O
clinical O O
use O O
of O O
SV40 B_VIRUS B_VIRUS[BIO]/B_DISEASE
vectors O O
has O O
been O O
hampered O O
by O O
production O O
and O O
safety O O
issues O O
. O O

Bi-directional O O
deflectable O O
catheters B_MEDICAL_DEVICE B_PRODUCT[OBJECT]/B_ORGANIZATION
lead O O
the O O
market O O
due O O
to O O
their O O
high O O
adoption O O
rate O O
and O O
availability O O
. O O

Based O O
on O O
previous O O
crops O O
grown O O
on O O
the O O
property, O O
MYM's O O
50% O O
entitlement O O
of O O
the O O
estimated O O
production O O
is O O
60,000 O O
lbs B_MEASURE B_MEASURE/B_LOCATION
of O O
biomass O O
. O O

Bio-Techne's O O
genomic O O
tools O O
include O O
advanced O O
tissue-based O O
in-situ O O
hybridization O O
assays O O
(ISH) O O
for O O
research O O
and O O
clinical O O
use, O O
sold O O
under O O
the O O
ACD B_ORGANIZATION B_ORGANIZATION/B_PERSON
brand O O
as O O
well O O
as O O
a O O
portfolio O O
of O O
clinical O O
molecular O O
diagnostic O O
oncology O O
assays, O O
including O O
the O O
IntelliScore O O
test O O
(EPI) O O
for O O
prostate O O
cancer O O
diagnosis O O
. O O

There O O
are O O
no O O
treatment O O
options O O
specifically O O
indicated O O
for O O
ACD B_DISEASE B_DISEASE
and O O
physicians O O
must O O
utilize O O
agents O O
approved O O
for O O
other O O
dermatology O O
conditions, O O
such O O
as O O
topical O O
corticosteroids, O O
which O O
are O O
able O O
to O O
manage O O
disease O O
symptoms O O
in O O
less O O
than O O
half O O
of O O
patients O O
and O O
have O O
well-known O O
side-effects O O
. O O

As O O
ACD B_DISEASE B_DISEASE/B_GENE
has O O
been O O
implicated O O
in O O
apoptosis-resistant O O
glioblastoma O O
(GBM), O O
there O O
is O O
a O O
high O O
medical O O
need O O
for O O
identifying O O
novel O O
ACD-inducing O O
drugs O O
. O O

patients O O
treated O O
with O O
anticancer O O
chemotherapy O O
drugs O O
( O O
ACD B_DISEASE B_DISEASE/B_LOCATION
) O O
are O O
vulnerable O O
to O O
infectious O O
diseases O O
due O O
to O O
immunosuppression O O
and O O
to O O
the O O
direct O O
impact O O
of O O
ACD B_DISEASE B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
their O O
intestinal O O
microbiota O O
. O O

Arm B_STUDY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_STUDY I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
designed O O
to O O
evaluate O O
the O O
ability O O
of O O
bemcentinib B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
prevent O O
acquired O O
resistance O O
to O O
EGFR B_GENE B_GENE/B_MEASURE
targeted O O
therapy O O
when O O
given O O
in O O
combination O O
with O O
erlotinib B_DRUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
first O O
line. O O

In O O
addition O O
to O O
HNSCC B_DISEASE B_DISEASE/B_GENE
, O O
EGFR B_GENE B_GENE
overexpression O O
has O O
been O O
associated O O
with O O
a O O
number O O
of O O
cancers B_DISEASE B_DISEASE
, O O
including O O
epithelial B_DISEASE B_DISEASE
tumors I_DISEASE I_DISEASE
of O O
the O O
head B_BODY_PART_OR_ORGAN_COMPONENT B_BODY_PART_OR_ORGAN_COMPONENT
and O O
neck B_BODY_PART_OR_ORGAN_COMPONENT B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
squamous B_DISEASE B_DISEASE
cell I_DISEASE I_DISEASE
cancers I_DISEASE I_DISEASE
of O O
the O O
lungs B_BODY_PART_OR_ORGAN_COMPONENT B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
anal B_DISEASE B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancers I_DISEASE I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
glioblastoma B_DISEASE B_DISEASE
. O O

Rakesh B_PERSON B_PERSON
Barve I_PERSON I_PERSON
fondly O O
recalls O O
scenes O O
from O O
Pulp B_ENT B_ENT/B_PERSON
Fiction I_ENT I_ENT/I_PERSON
directed O O
by O O
Quentin B_PERSON B_PERSON
Tarantino I_PERSON I_PERSON
and O O
filmed O O
mostly O O
in O O
California B_LOCATION B_LOCATION
. O O

Dr B_PERSON B_PERSON
Praveen I_PERSON I_PERSON
Kumar I_PERSON I_PERSON
advocates O O
wearing O O
masks O O
in O O
public O O
places O O
to O O
reduce O O
the O O
risk O O
of O O
covid B_DISEASE B_DISEASE
. O O

Paul B_PERSON B_PERSON
Erdos I_PERSON I_PERSON
died O O
at O O
83 B_NUMBER B_NUMBER[MEASURE]/B_LOCATION
. O O

Fyodor B_PERSON B_PERSON
Mikhailovich I_PERSON I_PERSON
Dostoevsky I_PERSON I_PERSON
was O O
treated O O
for O O
Parkinsons B_DISEASE B_DISEASE
. O O

Stanford B_LOCATION B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
called O O
. O O

Parkinsons B_PERSON B_PERSON/B_LOCATION
dad O O
flew O O
from O O
SFO B_LOCATION B_LOCATION/B_ORGANIZATION
to O O
New B_LOCATION B_LOCATION
York I_LOCATION I_LOCATION
. O O

He O O
graduated O O
from O O
Stanford B_LOCATION B_LOCATION
with O O
a O O
master's O O
degree O O
in O O
Physics O O
and O O
astronomy O O
. O O

Lionel B_PERSON B_PERSON
Ritchie I_PERSON I_PERSON
topped O O
the O O
singles O O
chart O O
in O O
the O O
early O O
eighties B_TIME B_TIME[MEASURE]
. O O

The O O
sky O O
turned O O
dark B_COLOR B_COLOR/B_LOCATION
in O O
advance O O
of O O
the O O
storm O O
that O O
was O O
coming O O
from O O
the O O
east O O
. O O

The O O
United B_LOCATION B_LOCATION
States I_LOCATION I_LOCATION
has O O
the O O
largest O O
prison O O
population O O
in O O
the O O
world, O O
and O O
the O O
highest O O
per-capita O O
incarceration O O
rate O O
. O O

She O O
loves O O
to O O
watch O O
Sunday O O
afternoon O O
football B_SPORT B_ENT
with O O
her O O
family O O
. O O

She O O
was O O
discriminated O O
against O O
because O O
she O O
was O O
black B_COLOR B_COLOR/B_DISEASE_ADJECTIVE[DISEASE]
. O O

His O O
faith O O
in O O
god B_PERSON B_PERSON/B_RELIGION[SOCIAL_CIRCUMSTANCES]
diminished O O
after O O
witnessing O O
human O O
suffering O O
all O O
around O O
him O O
. O O

lou B_PERSON B_PERSON
gehrig I_PERSON I_PERSON
was O O
diagnosed O O
with O O
Parkinson's B_DISEASE B_DISEASE/B_GENE
. O O

lou B_PERSON B_PERSON
gehrig I_PERSON I_PERSON
was O O
diagnosed O O
with O O
Parkinson B_DISEASE B_DISEASE/B_GENE
. O O

Parkinson B_PERSON B_PERSON
was O O
diagnosed O O
with O O
lou B_DISEASE B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gehrig I_DISEASE I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Parkinson B_PERSON B_PERSON
was O O
diagnosed O O
with O O
lou B_DISEASE B_DISEASE
gehrig I_DISEASE I_DISEASE
disease I_DISEASE I_DISEASE
. O O

Parkinson B_PERSON B_PERSON
was O O
diagnosed O O
with O O
lou B_DISEASE B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Parkinson B_PERSON B_PERSON
was O O
diagnosed O O
with O O
ALS B_DISEASE B_DISEASE
. O O

Parkinson B_PERSON B_PERSON
was O O
diagnosed O O
with O O
lou B_DISEASE B_DISEASE
gehrig's I_DISEASE I_DISEASE
. O O

Lou B_PERSON B_PERSON
Gehrig I_PERSON I_PERSON
who O O
works O O
for O O
XCorp B_ORGANIZATION B_ORGANIZATION/B_PERSON
and O O
lives O O
in O O
New B_LOCATION B_LOCATION
York I_LOCATION I_LOCATION
suffers O O
from O O
Parkinson's B_DISEASE B_DISEASE
. O O

I O O
met O O
my O O
girl B_PERSON B_PERSON/B_NUMBER[MEASURE]
friends O O
at O O
the O O
pub B_LOCATION B_LOCATION
. O O

I O O
met O O
my O O
XCorp B_NUMBER B_NUMBER[MEASURE]/B_ORGANIZATION
friends O O
at O O
the O O
pub B_LOCATION B_LOCATION
. O O

I O O
met O O
my O O
two B_NUMBER B_NUMBER[MEASURE]/B_PERSON
friends O O
at O O
the O O
pub B_LOCATION B_LOCATION
. O O

I O O
met O O
my O O
girl B_PERSON B_PERSON/B_ENT
friends I_PERSON I_PERSON/I_ENT
at O O
the O O
pub B_LOCATION B_LOCATION
. O O

I O O
met O O
my O O
New B_PERSON B_PERSON/B_ORGANIZATION
York I_PERSON I_PERSON/I_ORGANIZATION
friends I_PERSON I_PERSON/I_ORGANIZATION
at O O
the O O
pub B_LOCATION B_LOCATION
. O O

I O O
met O O
my O O
XCorp B_PERSON B_PERSON/B_ORGANIZATION
friends I_PERSON I_PERSON/I_ORGANIZATION
at O O
the O O
pub B_LOCATION B_LOCATION
. O O

I O O
met O O
my O O
two B_PERSON B_PERSON/B_ENT
friends I_PERSON I_PERSON/I_ENT
at O O
the O O
pub B_LOCATION B_LOCATION
. O O

He O O
was O O
diagnosed O O
with O O
non B_DISEASE B_DISEASE
small I_DISEASE I_DISEASE
cell I_DISEASE I_DISEASE
lung I_DISEASE I_DISEASE
cancer I_DISEASE I_DISEASE
. O O

He O O
was O O
diagnosed O O
with O O
non O O
small_ O O
cell O O
lung O O
cancer B_DISEASE B_DISEASE
. O O

he O O
suffers O O
from O O
colorectal O O
cancer B_DISEASE B_DISEASE
. O O

he O O
suffers O O
from O O
colorectal B_DISEASE B_DISEASE
cancer I_DISEASE I_DISEASE
. O O

he O O
flew O O
from O O
frigid O O
New B_LOCATION B_LOCATION
York I_LOCATION I_LOCATION
to O O
sunny B_LOCATION B_LOCATION
Alabama I_LOCATION I_LOCATION
. O O

he O O
flew O O
from O O
frigid O O
New B_LOCATION B_LOCATION
York I_LOCATION I_LOCATION
to O O
sunny O O
Alabama B_LOCATION B_LOCATION
. O O

I O O
thank O O
my O O
Beijing B_LOCATION B_LOCATION/B_NUMBER[MEASURE]
friends O O
and O O
wish O O
everyone O O
a O O
Happy B_TIME B_TIME[MEASURE]/B_PERSON
New I_TIME I_TIME[MEASURE]/I_PERSON
Year I_TIME I_TIME[MEASURE]/I_PERSON
. O O

I O O
thank O O
my O O
Bari B_PERSON B_PERSON/B_ENT
friends I_PERSON I_PERSON/I_ENT
and O O
wish O O
everyone O O
a O O
Happy O O
Casimir B_TIME B_TIME[MEASURE]/B_PERSON
Pulaski I_TIME I_TIME[MEASURE]/I_PERSON
Day I_TIME I_TIME[MEASURE]/I_PERSON
. O O

I O O
admire O O
my O O
Bari B_PERSON B_PERSON/B_ORGANIZATION
roommates I_PERSON I_PERSON/I_ORGANIZATION
and O O
wish O O
everyone O O
a O O
Happy O O
Casimir B_TIME B_TIME[MEASURE]/B_PERSON
Pulaski I_TIME I_TIME[MEASURE]/I_PERSON
Day I_TIME I_TIME[MEASURE]/I_PERSON
. O O

I O O
thank O O
my O O
Beijing B_PERSON B_PERSON/B_ORGANIZATION
friends I_PERSON I_PERSON/I_ORGANIZATION
and O O
wish O O
everyone O O
a O O
Happy B_TIME B_TIME[MEASURE]/B_PERSON
New I_TIME I_TIME[MEASURE]/I_PERSON
Year I_TIME I_TIME[MEASURE]/I_PERSON
. O O

I O O
thank O O
my O O
Bari B_LOCATION B_LOCATION/B_NUMBER[MEASURE]
friends O O
and O O
wish O O
everyone O O
a O O
Happy O O
Casimir B_TIME B_TIME[MEASURE]/B_PERSON
Pulaski I_TIME I_TIME[MEASURE]/I_PERSON
Day I_TIME I_TIME[MEASURE]/I_PERSON
. O O

I O O
admire O O
my O O
Bari B_LOCATION B_LOCATION/B_NUMBER[MEASURE]
roommates O O
and O O
wish O O
everyone O O
a O O
Happy O O
Casimir B_TIME B_TIME[MEASURE]/B_PERSON
Pulaski I_TIME I_TIME[MEASURE]/I_PERSON
Day I_TIME I_TIME[MEASURE]/I_PERSON
. O O

